(Q46472588)

22 December 2017

title

Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer (English)

1 reference

22 December 2017

1 reference

G Treiber

1

1 reference

22 December 2017

T Wex

series ordinal

2

1 reference

22 December 2017

P Malfertheiner

series ordinal

3

1 reference

22 December 2017

publication date

19 July 2008

1 reference

22 December 2017

Journal of Cancer Research and Clinical Oncology

published in

1 reference

22 December 2017

volume

135

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

271-281

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1007/s00432-008-0443-x

exact match

0 references

cites work

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-008-0443-X

Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-008-0443-X

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-008-0443-X

Hepatocellular carcinoma: correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrast-enhanced computed tomography

21 January 2018

1 reference

12 December 2020

Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial

1 reference

12 December 2020

Antiangiogenic effects of somatostatin analogues

1 reference

12 December 2020

Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts

1 reference

12 December 2020

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

1 reference

12 December 2020

Octreotide therapy for advanced hepatocellular carcinoma

1 reference

12 December 2020

Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy

1 reference

12 December 2020

Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide

1 reference

12 December 2020

High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study.

1 reference

12 December 2020

Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma

1 reference

12 December 2020

Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer

1 reference

12 December 2020

The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update

1 reference

12 December 2020

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

1 reference

12 December 2020

Systemic treatment of hepatocellular carcinoma

1 reference

12 December 2020

Treatment of hepatocellular carcinoma with long acting somatostatin analogues.

1 reference

12 December 2020

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

1 reference

12 December 2020

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

1 reference

12 December 2020

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

1 reference

12 December 2020

Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo

1 reference

12 December 2020

Serum Soluble Vascular Cell Adhesion Molecule-1: Role as a Surrogate Marker of Angiogenesis

1 reference

12 December 2020

Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function

1 reference

12 December 2020

1 reference

12 December 2020

sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation

1 reference

12 December 2020

Hepatocellular carcinoma

1 reference

12 December 2020

Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage

1 reference

12 December 2020

Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo

1 reference

12 December 2020

Increasing tumor uptake of anticancer drugs with imatinib.

1 reference

12 December 2020

Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis

1 reference

12 December 2020

PDGF receptors as cancer drug targets

1 reference

12 December 2020

Prognostic molecular markers in hepatocellular carcinoma: a systematic review

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors

1 reference

12 December 2020

Management of hepatocellular carcinoma

1 reference

12 December 2020

Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study

1 reference

12 December 2020

Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities.

1 reference

12 December 2020

The role of sandostatin LAR in treating patients with advanced hepatocellular cancer.

1 reference

12 December 2020

Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.

1 reference

12 December 2020

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

10.1007/S00432-008-0443-X

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

18642029

1 reference

22 December 2017